N@N

Facet Biotech Corporation: Facet Biotech Appoints Mark Rolfe, Ph.D. as Senior Vice President and Chief Scientific Officer

^{Published on 2009-07-09 05:44:18, Last Modified on 2009-07-09 05:44:26 - Market Wire}
 

REDWOOD CITY, CA--(Marketwire - July 9, 2009) - Facet Biotech Corporation (NASDAQ: [ FACT ]) today announced the appointment of Mark Rolfe, Ph.D., as Senior Vice President and Chief Scientific Officer. Dr. Rolfe will be responsible for leading the company's research efforts, including target validation, translational medicine and protein engineering technologies. He will join the company on August 20, 2009.

"We are very pleased to have a scientist and leader of Mark's caliber join Facet," said Faheem Hasnain, president and chief executive officer. "Mark brings a tremendous amount of experience and insight in oncology that will be instrumental in solidifying Facet as a leader in oncology therapeutics development. Mark and his organization will play a vital role in ensuring that our molecules are developed and progressed with a clear understanding of the biological context and ultimately the appropriate patient population."

Since 1999, Dr. Rolfe held various positions of increasing responsibility at Millennium: The Takeda Oncology Company, most recently as Vice President, Oncology Discovery. From 1993 to 1999, Dr. Rolfe worked at Mitotix, Inc., where he last served as Director, Molecular Biology. From 1989 to 1993, Dr. Rolfe worked at Celltech Ltd., where he last served as Principal Scientist. Prior to Celltech, he completed post-doctoral fellowships at the Columbia University College of Physicians and Surgeons in New York and the Imperial Cancer Research Fund in London. He received his Ph.D. from the National Institute for Medical Research, London, and his B.A. and M.A. from Brasenose College, Oxford University.

About Facet Biotech

Facet Biotech is a biotechnology company dedicated to advancing its pipeline of four clinical-stage products and leveraging its research and development capabilities to identify and develop new oncology drugs. Facet Biotech Corporation launched in December 2008 as a spin-off from PDL BioPharma, Inc.

NOTE: Facet Biotech and the Facet Biotech logo are considered trademarks of Facet Biotech Corporation.